Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08EWE
|
|||
Drug Name |
Plitidepsin
|
|||
Synonyms |
plitidepsin; Aplidine; Dehydrodidemnin B; UNII-Y76ID234HW; 137219-37-5; Y76ID234HW; CHEBI:90205; Plitidepsin [INN:BAN]; plitidepsina; plitidepsium; plitidepsine; Plitidepsin (INN); Didemnin A, N-(1-(1,2-dioxopropyl)-L-prolyl)-; CHEMBL451930; 2-9-Didemnin B, 2-(1-(1,2-dioxopropyl)-L-proline)-; SCHEMBL13413427; DB04977; Z-3094; D11032; Q4779975; Y-100032; Plitidepsin
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 1 | [1] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
![]() |
Download2D MOL
|
||
Formula |
C57H87N7O15
|
|||
Canonical SMILES |
CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
|
|||
InChI |
1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
|
|||
InChIKey |
UUSZLLQJYRSZIS-LXNNNBEUSA-N
|
|||
CAS Number |
CAS 137219-37-5
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:90205
|
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04382066) Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.